




Patent Landscape

Patenting activity related to COVID-19 Therapeutics

This infographic provides observations on the patenting activity which took place in the field of COVID-19 Therapeutic throughout the pandemic, from January 2020 to September 2022.

Distribution of patent applications across therapeutic categories and subcategories


Patents related to small molecule therapeutics dominate the dataset, followed by patents related to biologic therapeutics.



Top COVID-19 Therapeutic patent applicants


The top therapeutic patent applicants were all universities and research organizations.

Companies Universities and research organizations




Applicant locations

The majority of patents related to COVID-19 therapeutics were filed by applicants located in China and the United States.



Top applicant locations in different COVID-19 therapeutics categories

While applicants in China and the United States filed about an equal number of small molecule and biologics-related patents, China-based applicants, filed many more patents disclosing the use of traditional medicine in treating patients with COVID-19. Applicants in the Republic of Korea and India likewise filed more traditional medicine patents compared to applicants in the United States.



Top applicant locations in different COVID-19 Biologics therapeutics subcategories

In COVID-19 biologics therapeutics platforms, China-based applicants filed more antibody patents, fewer protein/peptide patents and fewer cell therapy patents compared to their US-based counterparts.

